Clinical Study

Phase II/III Biomarker-Driven Master Protocol For Second Line Therapy Of Squamous Cell Lung Cancer (Screening Step).

Posted Date: Sep 21, 2017

  • Investigator: John Morris
  • Specialties: Lung Cancer, Cancer
  • Type of Study: Drug

The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study.


To Be Eligible For This Study, Patients Must Have Squamous Cell Lung Cancer.


Cancer, Lung Cancer, S1400, Squamous Cell

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.